Abstract:NQO2 is an NRH-dependent quinone reductase that catalyzes the two-electron reduction of quinones to their corresponding hydroquinones. Despite structural similarities between NAD(P)H quinone oxidoreductase 1 (NQO1) and NQO2 many compounds have been shown to bind selectively to NQO2. Previous studies have shown that many drugs including resveratrol, quercetin, chloroquine, and imatinib can bind to and inhibit the catalytic activity of NQO2. Whether the binding and inhibition of NQO2 influences the pharmacology of these compounds is currently unknown. In this study we have developed a series of indolequinones as mechanism-based inhibitors of NQO2. These compounds were based on ES936 (5-methoxy-1,2-dimethyl-3-(4-nitrophenoxy)methylindole-4,7-dione) an efficient mechanism-based inhibitor of NQO1. We found that substitution of the 5-methoxy group in ES936 with an aminoalkylamino side chain generated potent mechanism-based inhibitors of NQO2 that do not efficiently inhibit NQO1. Interestingly, MD436 (5-amino-1,2-dimethyl-3-(2,4,6-trifluorophenoxy)methylindole-4,7-dione) a compound that contains only an amino group at the 5-position was a mechanism-based inhibitor of NQO1 and NQO2. Structural requirements for optimal inhibition of NQO2 were examined and found to include an aminoalkylamino side chain at the 5-position. NQO2 inhibition was observed with compounds with alkyl chains that varied from 3 to 8 carbons in length, with maximal inhibition observed with compounds that possessed chain lengths of between 3 to 5 carbons. Compounds where the aminoalkyl chain terminated in either an unsubstituted amino group or a dimethyl substituted amino group were efficient inhibitors of NQO2. Compounds with substitutions at the 6-position were not efficient mechanism-based inhibitors of NQO2 despite molecular docking studies that suggested NQO2 could accommodate either 5 or 6-position aminoalkylamino side chains. Co-crystallization studies are currently underway to more precisely define the physical interactions between compounds substituted at the 5-position and NQO2. As previously observed for a series of NQO1 mechanism-based inhibitors, structural requirements for efficient inhibition of NQO2 also include a methyl group at the 2-position of the indole ring and a substituent at the 3-position capable of leaving to generate a reactive iminium electrophile following enzymatic reduction. MD372 (5-(3-aminopropylamino)-1,2-dimethyl-3-(2,4,6-trifluorophenoxy)methylindole-4,7-dione) was tested for NQO2 inhibition using the human leukemia cell line K562 that has been shown to contain very high levels of NQO2 protein and activity. Treatment of K562 cells with MD372 (100nM) for 15 min resulted in greater than 95% inhibition of NQO2 catalytic activity, confirming that these compounds enter cells and efficiently inhibit NQO2 (Supported by R21 HL095995). Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 5471.

The Inhibitory Effect of Azidosalic Amides on the SQR and QCR Activities of Purified Succinate Cytochrome C Reductase

Sensitivity of the Inhibitory Effect of Nitrosalicyl N Methylamide on Ubiquinol Cytochrome C Reductase to Ubiquinol

Computational and experimental insight into the molecular mechanism of carboxamide inhibitors of succinate-ubquinone oxidoreductase

Effect of respiratory inhibitors and quinone analogues on the aerobic electron transport system of Eikenella corrodens

Interference in mevalonate pathway ameliorates homocysteine-induced endothelium-dysfunction.

Defining the mechanism of action of S1QELs, specific suppressors of superoxide production in the quinone-reaction site in mitochondrial complex I

Design, synthesis and inhibitory activity of novel 2, 3-dihydroquinolin-4(1H)-one derivatives as potential succinate dehydrogenase inhibitors

Modulation of the Activity of Succinate Dehydrogenase by Acetylation with Chemicals, Drugs, and Microbial Metabolites

3,5-Diaryl substituted sclerotiorin: a novel scaffold of succinate-ubiquinone oxidoreductase inhibitors

Discovery of Novel Aminocyclobutanecarboxylic Acid Derivatives As Succinate Dehydrogenase Inhibitors.

Interaction of 6-Bromo- and 6-Chloro-Ubiquinone derivatives with mitochondrial electron transfer system

Selective Removal of Aminoquinoline Auxiliary by IBX Oxidation

Thiosulfate Oxidation in Sulfur-Reducing Shewanella Oneidensis and Its Unexpected Influences on the Cytochrome C Content.

In silico evaluation of a new compound incorporating 4(3H)-quinazolinone and sulfonamide as a potential inhibitor of a human carbonic anhydrase

Abstract 5471: Mechanism-based inhibition of NRH: quinone oxidoreductase 2 (NQO2) by a series of aminoalkylamino substituted indolequinones

Inhibitors of a Na+-pumping NADH-ubiquinone oxidoreductase play multiple roles to block enzyme function

Inhibition of Intracellular Succinate Dehydrogenase of the Bacillus subtilis Bacterium as a Criterion for the Involvement of an Enzyme in the Reduction of Chloride Iodonitrotetrazolium, an Indicator of Cell Viability

In Situ Spectroeletrochemistry and Cytotoxic Activities of Natural Ubiquinone Analogues

The quaternary structure of the Saccharomyces cerevisiae succinate dehydrogenase. Homology modeling, cofactor docking, and molecular dynamics simulation studies

Fumarate reductase activity of bovine heart succinate-ubiquinone reductase. New assay system and overall properties of the reaction

Electrochemical Synthesis of Isoquinoline Sulfone Compounds and Study of Their Inhibition of Acetolactate Synthase Enzyme Activity